Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JQAJB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
MGTA-117
|
|||||
| Synonyms |
Anti-CD117 amanitin ADC; Anti-CD117 amanitin antibody drug conjugate; CD117-amanitin antibody drug conjugate; MGTA 117; anti-CD117 (c-KIT)-amanitin antibody-drug conjugate
Click to Show/Hide
|
|||||
| Organization |
Heidelberg Pharma AG
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Indication |
In total 4 Indication(s)
Acute myelogenous leukemia [ICD11:2B33]
Phase 2
Myelodysplastic syndrome [ICD11:2A37]
Phase 1
Lysosomal storage disease [ICD11:5C56]
Clinical candidate
Sickle cell disease [ICD11:3A51]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Mast/stem cell growth factor receptor Kit (KIT)
|
Antigen Info | ||||
| Payload Name |
Alpha-amanitin
|
Payload Info | ||||
| Therapeutic Target |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.